506 related articles for article (PubMed ID: 30919549)
1. Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk score.
O'Connor C; Fiuzat M; Mulder H; Coles A; Ahmad T; Ezekowitz JA; Adams KF; Piña IL; Anstrom KJ; Cooper LS; Mark DB; Whellan DJ; Januzzi JL; Leifer ES; Felker GM
Eur J Heart Fail; 2019 Jun; 21(6):770-778. PubMed ID: 30919549
[TBL] [Abstract][Full Text] [Related]
2. Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
Felker GM; Anstrom KJ; Adams KF; Ezekowitz JA; Fiuzat M; Houston-Miller N; Januzzi JL; Mark DB; Piña IL; Passmore G; Whellan DJ; Yang H; Cooper LS; Leifer ES; Desvigne-Nickens P; O'Connor CM
JAMA; 2017 Aug; 318(8):713-720. PubMed ID: 28829876
[TBL] [Abstract][Full Text] [Related]
3. Clinical Significance of Get With the Guidelines-Heart Failure Risk Score in Patients With Chronic Heart Failure After Hospitalization.
Suzuki S; Yoshihisa A; Sato Y; Kanno Y; Watanabe S; Abe S; Sato T; Oikawa M; Kobayashi A; Yamaki T; Kunii H; Nakazato K; Ishida T; Takeishi Y
J Am Heart Assoc; 2018 Sep; 7(17):e008316. PubMed ID: 30371158
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction.
McDowell K; Kondo T; Talebi A; Teh K; Bachus E; de Boer RA; Campbell RT; Claggett B; Desai AS; Docherty KF; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Simpson J; Vaduganathan M; Jhund PS; Solomon SD; McMurray JJV
JAMA Cardiol; 2024 May; 9(5):457-465. PubMed ID: 38536153
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
[TBL] [Abstract][Full Text] [Related]
6. S
Sun J; Xie Z; Ye M; Xu H; Dong Y; Liu C; Zhu W
ESC Heart Fail; 2024 Jun; 11(3):1422-1434. PubMed ID: 38327133
[TBL] [Abstract][Full Text] [Related]
7. Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
Kristensen SL; Jhund PS; Køber L; McKelvie RS; Zile MR; Anand IS; Komajda M; Cleland JGF; Carson PE; McMurray JJV
JACC Heart Fail; 2015 Jun; 3(6):478-486. PubMed ID: 26046842
[TBL] [Abstract][Full Text] [Related]
8. Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure.
Wolsk E; Claggett B; Køber L; Pocock S; Yusuf S; Swedberg K; McMurray JJV; Granger CB; Pfeffer MA; Solomon SD
Eur J Heart Fail; 2018 Mar; 20(3):504-510. PubMed ID: 29193462
[TBL] [Abstract][Full Text] [Related]
9. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
[TBL] [Abstract][Full Text] [Related]
10. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
[TBL] [Abstract][Full Text] [Related]
11. Factors related to morbidity and mortality in patients with chronic heart failure with systolic dysfunction: the HF-ACTION predictive risk score model.
O'Connor CM; Whellan DJ; Wojdyla D; Leifer E; Clare RM; Ellis SJ; Fine LJ; Fleg JL; Zannad F; Keteyian SJ; Kitzman DW; Kraus WE; Rendall D; Piña IL; Cooper LS; Fiuzat M; Lee KL
Circ Heart Fail; 2012 Jan; 5(1):63-71. PubMed ID: 22114101
[TBL] [Abstract][Full Text] [Related]
12. Meta-Analysis Global Group in Chronic (MAGGIC) Heart Failure Risk Score: Validation of a Simple Tool for the Prediction of Morbidity and Mortality in Heart Failure With Preserved Ejection Fraction.
Rich JD; Burns J; Freed BH; Maurer MS; Burkhoff D; Shah SJ
J Am Heart Assoc; 2018 Oct; 7(20):e009594. PubMed ID: 30371285
[TBL] [Abstract][Full Text] [Related]
13. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.
Ambrosy AP; Vaduganathan M; Mentz RJ; Greene SJ; Subačius H; Konstam MA; Maggioni AP; Swedberg K; Gheorghiade M
Am Heart J; 2013 Feb; 165(2):216-25. PubMed ID: 23351825
[TBL] [Abstract][Full Text] [Related]
14. Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Heart Failure Network).
Ambrosy AP; Bhatt AS; Gallup D; Anstrom KJ; Butler J; DeVore AD; Felker GM; Fudim M; Greene SJ; Hernandez AF; Kelly JP; Samsky MD; Mentz RJ
Am J Cardiol; 2017 Jul; 120(1):98-105. PubMed ID: 28479167
[TBL] [Abstract][Full Text] [Related]
15. The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study.
Ibrahim NE; Januzzi JL
Curr Heart Fail Rep; 2018 Apr; 15(2):37-43. PubMed ID: 29468530
[TBL] [Abstract][Full Text] [Related]
16. Recovered heart failure with reduced ejection fraction and outcomes: a prospective study.
Lupón J; Díez-López C; de Antonio M; Domingo M; Zamora E; Moliner P; González B; Santesmases J; Troya MI; Bayés-Genís A
Eur J Heart Fail; 2017 Dec; 19(12):1615-1623. PubMed ID: 28387002
[TBL] [Abstract][Full Text] [Related]
17. ST2 elevation in heart failure, predictive of a high early mortality.
Dalal JJ; Digrajkar A; Das B; Bansal M; Toomu A; Maisel AS
Indian Heart J; 2018; 70(6):822-827. PubMed ID: 30580851
[TBL] [Abstract][Full Text] [Related]
18. Changes in natriuretic peptides after acute hospital presentation for heart failure with preserved ejection fraction: A feasible surrogate trial endpoint? A report from the prospective Karen study.
Savarese G; Donal E; Hage C; Oger E; Persson H; Daubert JC; Linde C; Lund LH;
Int J Cardiol; 2017 Jan; 226():65-70. PubMed ID: 27788392
[TBL] [Abstract][Full Text] [Related]
19. N-Terminal Pro-B-Type Natriuretic Peptide-Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations-Results From TIME-CHF.
Davarzani N; Sanders-van Wijk S; Karel J; Maeder MT; Leibundgut G; Gutmann M; Pfisterer ME; Rickenbacher P; Peeters R; Brunner-la Rocca HP
J Card Fail; 2017 May; 23(5):382-389. PubMed ID: 28232046
[TBL] [Abstract][Full Text] [Related]
20. Circulating microRNA-132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure.
Masson S; Batkai S; Beermann J; Bär C; Pfanne A; Thum S; Magnoli M; Balconi G; Nicolosi GL; Tavazzi L; Latini R; Thum T
Eur J Heart Fail; 2018 Jan; 20(1):78-85. PubMed ID: 29027324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
